| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | shikonin | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.014 | 0.6 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.7 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |